Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study.

Huffman DM, McLean GW, Seagrove MA

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Nov 2009Cited by 18 (Europe PMC)

PMID19546056DOI10.4158/ep09044.orr1PepBankPUB-19546056

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, hemoglobin A1c decreased during continuous pramlintide infusion.
In plain wordsIn patients with type 1 diabetes, hemoglobin A1c decreased from baseline during continuous pramlintide infusion.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHemoglobin A1c
Study
n = 11
Outcome group
Glycemic control · Metabolic and weight
Studied dose
9 microg/h basal infusion; premeal bolus titrated from 15 to 60 microg · subcutaneous infusion · 16 weeksAs given in this study (human).
Measurements
A1c
7.85%
week 16
A1c change
−0.35%
week 16
Source sentences
Summary
After 16 weeks of pramlintide therapy, mean +/- SD hemoglobin A1c decreased to 7.85% +/- 0.74% (-0.35%).
4 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, open-label, single-arm pilot study enrolled 11 patients (mean +/- SD values: age, 39.9 +/- 4.0 years; hemoglobin A1c, 8.20% +/- 0.60%; weight, 92.3 +/- 18.4 kg; body mass index, 29.7 +/- 5.1 kg/m2) with longterm type 1 diabetes mellitus (20.7 +/- 1.3 years; duration of pump therapy, 9.5 +/- 6.0 years).
Summary · context
Pramlintide basal infusion was begun with continuous subcutaneous infusion at 9 microg/h.
Summary · context
After 3 days, premeal bolus doses of pramlintide were initiated at 15 microg and titrated to 60 microg per meal.
Summary · context
Basal and bolus insulin doses were reduced 10% on initiation of CSPI and adjusted thereafter as needed to prevent hypoglycemia.
Report a problemFND-1954605601
02HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, fasting glucose decreased during continuous pramlintide infusion.
In plain wordsIn patients with type 1 diabetes, fasting glucose decreased from baseline during continuous pramlintide infusion.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseFasting glucose
Study
n = 11
Outcome group
Glycemic control · Metabolic and weight
Studied dose
9 microg/h basal infusion; premeal bolus titrated from 15 to 60 microg · subcutaneous infusion · 16 weeksAs given in this study (human).
Measurements
Fasting glucose
198.2 mg/dL
baseline
Fasting glucose
135.8 mg/dL
after therapy
Source sentences
Summary
The fasting glucose level declined from 198.2 +/- 66.9 mg/dL to 135.8 +/- 63.9 mg/dL.
4 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, open-label, single-arm pilot study enrolled 11 patients (mean +/- SD values: age, 39.9 +/- 4.0 years; hemoglobin A1c, 8.20% +/- 0.60%; weight, 92.3 +/- 18.4 kg; body mass index, 29.7 +/- 5.1 kg/m2) with longterm type 1 diabetes mellitus (20.7 +/- 1.3 years; duration of pump therapy, 9.5 +/- 6.0 years).
Summary · context
Pramlintide basal infusion was begun with continuous subcutaneous infusion at 9 microg/h.
Summary · context
After 3 days, premeal bolus doses of pramlintide were initiated at 15 microg and titrated to 60 microg per meal.
Summary · context
Basal and bolus insulin doses were reduced 10% on initiation of CSPI and adjusted thereafter as needed to prevent hypoglycemia.
Report a problemFND-1954605602
03HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, weight decreased during continuous pramlintide infusion.
In plain wordsIn patients with type 1 diabetes, weight decreased from baseline during continuous pramlintide infusion.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseWeight
Study
n = 11
Outcome group
Body weight · Metabolic and weight
Studied dose
9 microg/h basal infusion; premeal bolus titrated from 15 to 60 microg · subcutaneous infusion · 12 weeksAs given in this study (human).
Measurements
Weight
91.8 kg
week 12
Weight change
−0.5 kg
week 12
Source sentences
Summary
The mean weight decreased to 91.8 +/- 20.1 kg (-0.5 kg) at week 12.
4 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, open-label, single-arm pilot study enrolled 11 patients (mean +/- SD values: age, 39.9 +/- 4.0 years; hemoglobin A1c, 8.20% +/- 0.60%; weight, 92.3 +/- 18.4 kg; body mass index, 29.7 +/- 5.1 kg/m2) with longterm type 1 diabetes mellitus (20.7 +/- 1.3 years; duration of pump therapy, 9.5 +/- 6.0 years).
Summary · context
Pramlintide basal infusion was begun with continuous subcutaneous infusion at 9 microg/h.
Summary · context
After 3 days, premeal bolus doses of pramlintide were initiated at 15 microg and titrated to 60 microg per meal.
Summary · context
Basal and bolus insulin doses were reduced 10% on initiation of CSPI and adjusted thereafter as needed to prevent hypoglycemia.
Report a problemFND-1954605603
04HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, daily bolus insulin requirement decreased during continuous pramlintide infusion.
In plain wordsIn patients with type 1 diabetes, daily mealtime insulin needs decreased from baseline during continuous pramlintide infusion.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBolus insulin requirement
Study
n = 11
Outcome group
Glycemic control · Metabolic and weight
Studied dose
9 microg/h basal infusion; premeal bolus titrated from 15 to 60 microg · subcutaneous infusion · 16 weeksAs given in this study (human).
Measurements
Bolus insulin decrease
20%
daily requirement
Source sentences
Summary
The daily bolus insulin requirement decreased 20%; daily basal insulin was unchanged (27.7 +/- 11.7 U).
4 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, open-label, single-arm pilot study enrolled 11 patients (mean +/- SD values: age, 39.9 +/- 4.0 years; hemoglobin A1c, 8.20% +/- 0.60%; weight, 92.3 +/- 18.4 kg; body mass index, 29.7 +/- 5.1 kg/m2) with longterm type 1 diabetes mellitus (20.7 +/- 1.3 years; duration of pump therapy, 9.5 +/- 6.0 years).
Summary · context
Pramlintide basal infusion was begun with continuous subcutaneous infusion at 9 microg/h.
Summary · context
After 3 days, premeal bolus doses of pramlintide were initiated at 15 microg and titrated to 60 microg per meal.
Summary · context
Basal and bolus insulin doses were reduced 10% on initiation of CSPI and adjusted thereafter as needed to prevent hypoglycemia.
Report a problemFND-1954605604
05HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, daily basal insulin was unchanged during continuous pramlintide infusion.
In plain wordsIn patients with type 1 diabetes, daily basal insulin did not change from baseline during continuous pramlintide infusion.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeBasal insulin requirement
Study
n = 11
Outcome group
Glycemic control · Metabolic and weight
Studied dose
9 microg/h basal infusion; premeal bolus titrated from 15 to 60 microg · subcutaneous infusion · 16 weeksAs given in this study (human).
Measurements
Basal insulin
27.7 U
daily
Source sentences
Summary
The daily bolus insulin requirement decreased 20%; daily basal insulin was unchanged (27.7 +/- 11.7 U).
4 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, open-label, single-arm pilot study enrolled 11 patients (mean +/- SD values: age, 39.9 +/- 4.0 years; hemoglobin A1c, 8.20% +/- 0.60%; weight, 92.3 +/- 18.4 kg; body mass index, 29.7 +/- 5.1 kg/m2) with longterm type 1 diabetes mellitus (20.7 +/- 1.3 years; duration of pump therapy, 9.5 +/- 6.0 years).
Summary · context
Pramlintide basal infusion was begun with continuous subcutaneous infusion at 9 microg/h.
Summary · context
After 3 days, premeal bolus doses of pramlintide were initiated at 15 microg and titrated to 60 microg per meal.
Summary · context
Basal and bolus insulin doses were reduced 10% on initiation of CSPI and adjusted thereafter as needed to prevent hypoglycemia.
Report a problemFND-1954605605
06HumanNon-randomized trialSafety outcome
All patients with type 1 diabetes experienced mild postprandial hypoglycemia during continuous pramlintide infusion.
In plain wordsAll patients with type 1 diabetes had mild low blood sugar after meals during continuous pramlintide infusion.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableMild postprandial hypoglycemia
Study
n = 11
Outcome group
Adverse events · Metabolic and weight
Studied dose
9 microg/h basal infusion; premeal bolus titrated from 15 to 60 microg · subcutaneous infusion · 16 weeksAs given in this study (human).
Source sentences
Summary
All patients experienced mild postprandial hypoglycemia, but no severe hypoglycemia was reported.
4 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, open-label, single-arm pilot study enrolled 11 patients (mean +/- SD values: age, 39.9 +/- 4.0 years; hemoglobin A1c, 8.20% +/- 0.60%; weight, 92.3 +/- 18.4 kg; body mass index, 29.7 +/- 5.1 kg/m2) with longterm type 1 diabetes mellitus (20.7 +/- 1.3 years; duration of pump therapy, 9.5 +/- 6.0 years).
Summary · context
Pramlintide basal infusion was begun with continuous subcutaneous infusion at 9 microg/h.
Summary · context
After 3 days, premeal bolus doses of pramlintide were initiated at 15 microg and titrated to 60 microg per meal.
Summary · context
Basal and bolus insulin doses were reduced 10% on initiation of CSPI and adjusted thereafter as needed to prevent hypoglycemia.
Report a problemFND-1954605606
07HumanNon-randomized trialSafety outcome
In patients with type 1 diabetes, no severe hypoglycemia was reported during continuous pramlintide infusion.
In plain wordsIn patients with type 1 diabetes, no severe low blood sugar was reported during continuous pramlintide infusion.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableSevere hypoglycemia
Study
n = 11
Outcome group
Adverse events · Metabolic and weight
Studied dose
9 microg/h basal infusion; premeal bolus titrated from 15 to 60 microg · subcutaneous infusion · 16 weeksAs given in this study (human).
Source sentences
Summary
All patients experienced mild postprandial hypoglycemia, but no severe hypoglycemia was reported.
4 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, open-label, single-arm pilot study enrolled 11 patients (mean +/- SD values: age, 39.9 +/- 4.0 years; hemoglobin A1c, 8.20% +/- 0.60%; weight, 92.3 +/- 18.4 kg; body mass index, 29.7 +/- 5.1 kg/m2) with longterm type 1 diabetes mellitus (20.7 +/- 1.3 years; duration of pump therapy, 9.5 +/- 6.0 years).
Summary · context
Pramlintide basal infusion was begun with continuous subcutaneous infusion at 9 microg/h.
Summary · context
After 3 days, premeal bolus doses of pramlintide were initiated at 15 microg and titrated to 60 microg per meal.
Summary · context
Basal and bolus insulin doses were reduced 10% on initiation of CSPI and adjusted thereafter as needed to prevent hypoglycemia.
Report a problemFND-1954605607
08HumanNon-randomized trialSafety outcome
In patients with type 1 diabetes, three participants experienced mild initial nausea during continuous pramlintide infusion.
In plain wordsIn patients with type 1 diabetes, three participants had mild nausea at the start of continuous pramlintide infusion.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableInitial nausea
Study
n = 11
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
9 microg/h basal infusion; premeal bolus titrated from 15 to 60 microg · subcutaneous infusion · 16 weeksAs given in this study (human).
Measurements
Participants with mild initial nausea
3 participants
of 11 study participants
Source sentences
Summary
Three of the 11 study participants experienced mild initial nausea, but all patients successfully titrated bolus doses to 60 microg within 3 weeks.
4 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, open-label, single-arm pilot study enrolled 11 patients (mean +/- SD values: age, 39.9 +/- 4.0 years; hemoglobin A1c, 8.20% +/- 0.60%; weight, 92.3 +/- 18.4 kg; body mass index, 29.7 +/- 5.1 kg/m2) with longterm type 1 diabetes mellitus (20.7 +/- 1.3 years; duration of pump therapy, 9.5 +/- 6.0 years).
Summary · context
Pramlintide basal infusion was begun with continuous subcutaneous infusion at 9 microg/h.
Summary · context
After 3 days, premeal bolus doses of pramlintide were initiated at 15 microg and titrated to 60 microg per meal.
Summary · context
Basal and bolus insulin doses were reduced 10% on initiation of CSPI and adjusted thereafter as needed to prevent hypoglycemia.
Report a problemFND-1954605608
09HumanNon-randomized trialSafety outcome
All patients with type 1 diabetes successfully titrated pramlintide boluses to 60 microg within 3 weeks.
In plain wordsAll patients with type 1 diabetes reached pramlintide bolus doses of 60 microg within 3 weeks.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableSuccessful bolus titration
Study
n = 11
Outcome group
Adverse events · Metabolic and weight
Studied dose
9 microg/h basal infusion; premeal bolus titrated from 15 to 60 microg · subcutaneous infusion · 16 weeksAs given in this study (human).
Source sentences
Summary
Three of the 11 study participants experienced mild initial nausea, but all patients successfully titrated bolus doses to 60 microg within 3 weeks.
4 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, open-label, single-arm pilot study enrolled 11 patients (mean +/- SD values: age, 39.9 +/- 4.0 years; hemoglobin A1c, 8.20% +/- 0.60%; weight, 92.3 +/- 18.4 kg; body mass index, 29.7 +/- 5.1 kg/m2) with longterm type 1 diabetes mellitus (20.7 +/- 1.3 years; duration of pump therapy, 9.5 +/- 6.0 years).
Summary · context
Pramlintide basal infusion was begun with continuous subcutaneous infusion at 9 microg/h.
Summary · context
After 3 days, premeal bolus doses of pramlintide were initiated at 15 microg and titrated to 60 microg per meal.
Summary · context
Basal and bolus insulin doses were reduced 10% on initiation of CSPI and adjusted thereafter as needed to prevent hypoglycemia.
Report a problemFND-1954605609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00502138

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

University Diabetes & Endocrine Consultantsn = 12Jul 2007 to Jan 2008

IDDM

Trial page ClinicalTrials.govUpdated 16 Jan 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.